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BACKGROUND: IMPETUS AND OUTCOMES WITH 
PARKINSON’S GENE THERAPY (GT) TRIALS
Parkinson’s disease (PD) is a chronic, progressive neurodegenera-
tive disease most widely recognized for the profound degeneration 
of mid-brain dopamine nigrostriatal neurons linked to serious 
motor symptoms.1 However, PD is far more complex than com-
monly appreciated, with multiple etiologic variables and pathogenic 
pathways, complex pathologies, and a wide range of central nervous 
system (CNS) and non-CNS symptoms (Table 1).2,3 Moreover, wide 
gaps in our understanding still exist at each disease level (i.e., etiol-
ogy, pathogenesis, pathology, symptoms), and the cause-effect rela-
tionships between them remain especially obscure. Arguably, the 
most well-characterized relationship exists with regard to nigros-
triatal degeneration linked to the key motor symptoms; currrent 
oral dopaminergic pharmaceuticals are effective in controlling 
these symptoms at early disease stages. However, the drugs’ effec-
tiveness decline with progressive pathology, leading to gradual 
incapacitation of patients by increased “off” time (i.e., periods of 
no symptomatic relief) and increasing side effects such as peak-
dose dyskinesias.1 Thus, adequate treatment of the nigrostriatal- 
mediated motor impairments continues to represent a significant 
unmet medical need, affecting over 4 million people worldwide.4 
Though a number of solutions have been conceived to improve 
the function of the degenerating dopaminergic system, translating 
these biopharmaceutical concepts to the clinic has been challenging 
due to obstacles associated with delivering macromolecules to the 
central nervous system in a persistent and targeted fashion.
Progress achieved in the realm of gene therapy (GT) over 
the past decade has offered solutions to many of the delivery 
constraints,5 and several aspects of PD present it overtly as an 
ideal clinical indication to target using GT: (i) the well-defined, 
localizable, and targetable neuronal systems involved with major 
motor symptoms, (ii) the need for relatively small titer and vol-
ume of vector targeted to those sites, which avoids the systemic 
circulation of immunogenic materials, and (iii) the large and 
increasing demand for improved therapeutics with an aging pop-
ulation,4 which in whole bolsters impact and financial support for 
research and development. Given this rationale, PD has, for bet-
ter or worse, become a key exemplar for CNS GT. To date, the 
results of completed PD GT trials have supported the safety of 
GT targeting in the brain and many have further confirmed the 
successfully targeted expression of bioactive proteins in specific 
brain sites. However, none of the programs has yet produced suf-
ficiently robust or reliable efficacy data to enable initiation of a 
pivotal phase 3 trial required for regulatory approval. We attempt 
to integrate the many successes and formidable challenges of GT 
treatment of PD, in an effort to seek the best path forward for PD 
and CNS GT as a whole.
THE LOOK-SEE APPROACH
As compared with conventional small molecule drug testing, GT 
in the CNS is limited with respect to establishing initial dosing, 
quantifying targeting success, and accessing a comprehensive 
gauge of transgene production and localization, all of which pro-
vide the basis for iterative improvement with traditional drug 
development. While we expect that such limitations are attrib-
utable to a short-lasting gap between demand and current tech-
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Over the past decade, nine gene therapy clinical trials for Parkinson’s disease (PD) have been initiated and completed. 
Starting with considerable optimism at the initiation of each trial, none of the programs has yet borne sufficiently robust 
clinical efficacy or found a clear path toward regulatory approval. Despite the immediately disappointing nature of the 
efficacy outcomes in these trials, the clinical data garnered from the individual studies nonetheless represent tangible 
and significant progress for the gene therapy field. Collectively, the clinical trials demonstrate that we have overcome 
the major safety hurdles previously suppressing central nervous system (CNS) gene therapy, for none produced any evi-
dence of untoward risk or harm after administration of various vector-delivery systems. More importantly, these studies 
also demonstrated controlled, highly persistent generation of biologically active proteins targeted to structures deep in 
the human brain. Therefore, a renewed, focused emphasis must be placed on advancing clinical efficacy by improving 
clinical trial design, patient selection and outcome measures, developing more predictive animal models to support clini-
cal testing, carefully performing retrospective analyses, and most importantly moving forward—beyond our past limits.
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poor predictive power and a loss of continuity and progress 
between successive trials.
Whereas continuing progress is being made in the visualiza-
tion of viral vectors as they are delivered to the brain (e.g., the use 
of gadolinium-containing liposomes coupled with magnetic reso-
nance imaging),6,7 there is currently no direct means to determine 
the distribution or magnitude of transgene expression, since pro-
tein expression with CNS GT trials is both generated and produced 
entirely within the confines of the human brain. Therefore, it is not 
yet possible to confirm proper dose selection or monitor dosing 
levels, as would normally be done using standard pharmacoki-
netic (i.e., plasma level) methods. This severely limits the predic-
tive and correlative strength of treatment endpoint measurements. 
One surrogate means by which transgene expression and function 
has been assessed is positron emission tomography (PET) imag-
ing coupled with radiolabeled L-Dopa.8 This approach has enabled 
the live imaging of the dopamine precursor’s uptake, which when 
compared to pretreatment levels can be directly informative to aro-
matic L-amino acid decarboxylase (AADC) and tyrosine hydroxy-
lase (TH) transgene production and function. One problem with 
this approach is the inadequacy of using such technology as a 
dosing criterion: a sufficient signal is not expected until weeks or 
months after vector is administered, making adjustments to dosing 
inefficient at best, even within the flexibility of a phase 1 trial.
Due to the relative blindness of the researcher/clinician to 
targeting and dosing data, the process of translating and vali-
dating clinical results from prior animal data in GT programs 
has been characterized a “look-see” or trial and error approach. 
While this approach can still enable iterative improvement and 
therapeutic success, as demonstrated by the continued improve-
ments to hemophilia GT treatment (discussed further below), it 
is not a paradigm easily applied to all drug development endeav-
ors. Moreover, the repeated efforts can widen the so-called “val-
ley of death” one confronts when attempting to move a program 
forward from initial, small open-label trials to the multi-center, 
double-blind, sham-surgery controlled trials required to establish 
efficacy. As we will point out in the next section, each of the PD 
approaches described below offer vivid examples of the look-see 
approach, often to the program’s detriment.
PARKINSON’S GT CLINICAL TRIALS TO DATE
To date, five divergent GT approaches have been developed to 
treat the major motor symptoms of PD, all with the use of AAV or 
lentivirus vector platforms (Table 2). Each of the clinical approaches 
has focused on aspects of the basal ganglia, a group of subcortical 
neural sites located near the base of the forebrain that communicate 
intimately with the cerebral cortex and other brain areas. Most GT 
approaches directly target the terminals of the degenerating nigros-
triatal neurons for gene delivery, while one approach indirectly 
attempts to resolve striatal neurochemical imbalance by increasing 
inhibitory control from the subthalamic nucleus.
Three of the five PD GT approaches have attempted to amelio-
rate motor symptoms by altering the neurochemical conductivity 
of neurons mediating the motor behavior. This general strategy 
has involved delivering neurotransmitter-producing enzymes. 
In a first clinical study, AAV2/GAD (adeno-associated viral vec-
tor serotype 2/glutamic acid decarboxylase (GABA), a combina-
tion of GAD-65 and GAD-67) was delivered to the subthalamic 
nucleus9,10 (Figure 1b). GAD catalyzes the synthesis of gamma-
aminobutyric acid, the major inhibitory neurotransmitter in the 
CNS, potentially providing lost inhibitory control in the basal 
ganglion motor system, thus restoring appropriate transynap-
tic balance. A second approach has attempted to improve the 
ability of the putamen to synthesize dopamine from exogenous 
L-Dopa (the immediate precursor for dopamine and the mainstay 
therapeutic for early-stage PD) by expressing the major L-DOPA-
converting enzyme AADC in the putamen. Whereas one clinical 
investigation used AAV to deliver this enzyme,8 a second study 
used a trisictronic (delivery of three transgenes from a single vec-
tor cassette) lenti-vector expressing AADC as well as TH and 
GTP-CH1 (guanosine 5′-triphosphate cyclohydrolase1), with the 
latter two enzymes also significantly contributing to dopamine’s 
synthesis11 (Figure 1c).
The final two of five PD GT approaches have employed a neu-
rotrophic factor delivery approach, which rather than directly 
attempting to modulate neuronal activity, instead confer “trophic” 
support to the dopaminergic and surrounding neuronal popula-
tions by inducing repair genes in activated cells12,13 (Figure 1c,e). 
This offers potential improvement in symptoms as well as delay 
in disease progression.5,14 Both neurotrophic GT investigations to 
date have used AAV2 as the delivery vector; the studies diverge 
merely in the choice of which of two structural and functional 
analog proteins (neurturin (NRTN) or glia cell–derived neu-
rotrophic factor (GDNF)) is packaged and expressed. Below we 
offer perspective on the outcomes of each of the PD GT clinical 
approaches to date.
Table 1 Complex etiology, pathogenesis, pathology, and symptomatology of Parkinson’s disease
Etiology Pathogenesis Pathology Symptoms
Genetic mutationsa (SNCAb, 
PINK1c, LRRK2d, PRKNe, DJ1 -or 
PARK7f, ATP13A2)
Mitochrondrial dysfunction Loss of function and gradual 
axonopathy/death of mid-brain 
dopamine neurons
Loss of voluntary motor function 
(bradykinesia, rigidity, tremors, and 
eventually postural instability)
Oxidative damage
α-synuclein misfolding (& 
possible prion-like reactions)
α-synuclein accumulation (Lewy 
bodies)
Apoptosis Tau phosphorylation Cognitive deficits; psychiatric issues; 
olfactory deficits; REM sleep disturbances, 
autonomic dysfunction (e.g., urinary/GI 
complications)
Environmental factors (e.g., 
age, pesticides, herbicides, head 
trauma, fertilizers)
Neuroinflammation Loss of function and gradual 
death of neurons in several other 
PNS and CNS neuronal systems
CNS, central nervous system; GI, gastrointestinal; PNS, peripheral nervous system; REM, rapid eye movement.
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AAV/GAD
Following publication of nonhuman efficacy and safety data10 
and the successful completion of the first safety and tolerability 
trial for PD GT,15 a single controlled phase 2 trial with AAV/GAD 
was initiated. The trial involved 45 total subjects (roughly 50:50, 
treated:sham) and was completed without serious incident.16 
Several interesting protocol innovations were employed, includ-
ing prescreening all subjects with 18F-fluorodeoxyglucose PET to 
help assure a definitive diagnosis of PD. While this investigation 
is unique in that it achieved statistical significance on the primary 
efficacy endpoint (i.e., UPDRS motor-off), which represents a sig-
nificant accomplishment in its own right, the clinical effect was 
described as “modest”.17 Indeed, even the significant primary end-
point produced only a 3.4-point difference on the UPDRS, part 
3 scale (clinician-scored motor evaluation), compared to sham 
control. Moreover, the slim statistical difference between groups 
(P = 0.04) likely positively influenced by the use of a reasonable, 
protocol-prescribed data analysis approach that would not meet 
the more rigorous “intent to treat” standards traditionally held by 
the US Food and Drug Administration (FDA). Specifically, five 
subjects, four of whom showed no benefit on the primary end-
point, were eliminated after the trial was completed because an 
magnetic resonance imaging-based review of the targeting iden-
tified their injections as being off-target.16 While two other effi-
cacy measurements (both clinical impressions rating scales) also 
showed statistical significance (P < 0.05), these effects were also 
quite modest (i.e., < ½ point difference), while 21 other efficacy 
endpoints, including those commonly considered important for 
confirming clinical benefit (e.g., PDQ-39; multiple motor diary 
scores), showed no difference between groups. Thus, despite tech-
nically meeting the primary endpoint, the efficacy data from this 
trial were modest at best, which likely was responsible for the 
trial’s sponsor (Neurologix, Fort Lee, NJ) discontinuing the AAV/
GAD program.
In retrospect, the AAV/GAD clinical trial highlighted several 
key early concerns for the PD GT field to consider: (i) whether 
modest nonhuman primate efficacy data (e.g., a 1-point improve-
ment versus control on a 32-point behavioral scale) justified mov-
ing into clinical testing, (ii) the disappointingly modest efficacy data 
generated in the clinic, and (iii) the need for such high exclusion 
rates of treated subjects. The latter concern hints at potential chal-
lenges in performing consistent, accurate intracranial targeting—a 
concern that continues to be addressed and potentially resolved,18 
albeit using real-time imaging instrumentation and methods not 















AAV2/GAD Ph1-uncontrolleda 2003 12 1 × 1012 Subthal Nuc (unilat) 50 Acceptable Advanced to Ph2




Ph1-uncontrolledc 2004 10 0.3 × 1012 Putamen (Bilat) 50 Acceptable Program suspended; 




Ph1-uncontrolledd 2007 6 0.3 × 1012 Putamen (Bilat) 50 Acceptable No further testing; 
revised Ph1 recently 




Ph1-uncontrollede 2005 12 0.54 × 1012 Putamen (Bilat) 5(10)** Acceptable Advanced to Ph2
Ph2A-double-blindf 2006 38 0.54 × 1012 Putamen (Bilat) 5(10)** Acceptable Mixed results; 
revised Ph1 
designed
Ph1-uncontrolledg 2009 6 2.4 × 1012 Put + SN (Bilat) 50 Acceptable Advanced to Ph2




Ph1/2-uncontrolled# 2008 15 Lentivirus 
dosing is not 
comparable to 
that of AAV##
Putamen (Bilat) Acceptable Program suspended; 
additional work 




Ph1-uncontrolledk 2013 Ongoing 0.7 × 1012 Putamen (Bilat) 150 N/A N/A
Synopsis Total of seven phase 




>139 Tested up to 
1 × 1012 vg 
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Targets have included 
subthalamic nucleus, 
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AAV, adeno-associated virus; SN, substantia nigra.
aKaplitt et al.15. bLeWitt et al. 201116. cChristine et al.22. dMuramatsu et al. 28. eMarks et al. 40. fMarks et al. 38. gBartus et al. 39. hBartus et al. 37. Palfi et al.91 kLonser90. 
*Twenty-two subjects were dosed but six were eliminated from efficacy analysis due to mistargeting of cannula. **Two 5 µl volumes infused via single needle tract 
~4 mm apart. # Described as a Phase 1/2 trial, this open label (uncontrolled) study does not differ substantially from many dose-escalation Phase 1 safety studies that 
include secondary efficacy endpoints; thus, the distinction appears to be more a semantic preference than a reflection of a substantial difference in study design. 
##  A five-fold dose range was tested involving 3 dose levels (1.9X107 transducing units (TU); 4.0X107 TU; 1.0X108 TU).
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yet available in most stereotactic surgical operating rooms. Perhaps 
more importantly, even the hint of exclusionary data, regardless 
of the specific circumstances, can mar the perceived integrity of 
the results, and discount the apparent maturity of the field at large. 
Here, the modest efficacy data may be best ascribed to modest 
non-human primate findings. However, as we will examine, such 
modest clinical efficacy reported in this initial trial foreshadowed 
that of each subsequent clinical trial, even where preclinical studies 
showed more robust results. This clinical disappointment, there-
fore, can best be examined in the broader context of PD GT.
AAV/AADC
Another early PD GT approach utilized AAV/AADC, which 
after showing preclinical efficacy in MPTP monkeys,8 moved 
into clinical testing for 15 moderately advanced subjects in an 
open-label phase 1 clinical trial. The protocol for this trial was 
publicly discussed at the recombinant DNA advisory commit-
tee in late 2003,19 but subjects were not treated until 1 year later, 
during which time Genzyme, Boston, MA acquired the program 
from Avigen (Alameda, CA).20 First, it is worth noting the success 
of this trial, which like the preceding AAV/GAD study, included 
preliminary evidence for safety.21,22 However, despite a reasonable 
scientific rationale and several animal studies demonstrating 
reasonably robust enhancement in nigrostriatal dopamine func-
tion with AAV2-AADC,8,23–25 the phase 1 trial found only very 
modest efficacy,17,26 and was even described as neither “clear cut” 
nor what “we needed” by a Genzyme spokesperson.27 A second 
phase 1 study was performed in Japan using the identical vector 
(provided by Genzyme) and dosing paradigm, as well as a simi-
lar clinical protocol.28 Not surprisingly, the open-label efficacy 
results were not markedly different from the trial conducted in the 
USA. Recently, Genzyme agreed to allow the program’s academic 
originators, in collaboration with Michael J. Fox Foundation for 
Parkinson’s Research (MJFF), to resurrect a modified version of 
the clinical program, admitting that without the MJFF financial 
support, the program would not likely have moved forward.27
The reinitiated program offers an example of the look-see 
approach currently necessary for CNS GT work, which given the 
10-year separation between studies, might allow for at least mar-
ginal redesign and advancement of the forthcoming study. First, 
we should reexamine the overriding approach: the use of AADC 
as the lynchpin of the clinical trial. Some researchers have ques-
tioned whether elevating levels of AADC is necessary or suffi-
cient to enhance dopamine, citing either the redundancy of other 
Figure 1 Illustration of Parkinson’s disease gene therapy strategies to date.(a) In a sagittal slice of the human brain, dopaminergic pathways are 
depicted projecting within various deep-brain basal ganglia structures particularly affected in Parkinson’s disease (PD), such as the substantia nigra 
(SN) projecting to the striatum (STR). (b) In the first gene therapy (GT) clinical trial for PD, adeno-associated virus (AAV) carrying genes encoding 
for glutamic acid decarboxylase (GAD), a gamma-aminobutyric acid (GABA)-producing enzyme, were delivered to the subthalamic nucleus (STN), 
to neurons projecting to, and ostensibly inhibiting hyperactive putaminal (PUT) neurons of the striatum. (c,d) The majority of PD GT clinical trials to 
date, including those incorporating neurotrophic factors (NRTN, GDNF) and dopamine-producing enzymes (AADC, TH) have targeted the therapeu-
tic vector to striatal neurons, relying on retrograde transport to the SN cell bodies to achieve maximal therapeutic response. Delivery of the therapeu-
tic vector directly to cell bodies of the SN has been used as an alternative or complementary strategy to overcome the transport deficiences in this 
pathological brain tissue in an attempt enhance therapeutic response. (e) One of the two major STR/SN gene therapy approaches involves expression 
and secretion of neurotrophic factors glial-derived neurotrophic factor (GDNF) or neurturin (NRTN) in SN neurons projecting to the striatum, and 
thereby attempting to repair the SN-STR dopamine pathway and restore its function. The other GT approach in this system relies on expression of 
enzymes aromatic L-amino acid decarboxylase (AADC) or tyrosine hydroxylase (TH), each of which is involved in the synthesis of dopamine from 
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decarboxylases in the CNS, or the maintained functionality of 
the decarboxylase activity in patients with advanced PD, who can 
often still benefit from low doses of L-Dopa.29 However, the pre-
clinical data are strikingly clear in terms of efficacy expectations,8 
and recent clinical successes with AAV/AADC in a compassion-
ate use study of AADC deficiency30 reaffirm the potential for this 
transgene to restore L-Dopa conversion to dopamine in humans 
(to the extent that the monogenic disease may be comparable to 
the complex etiology of PD). Thus, an alternative explanation for 
the lack of efficacy might be due to delivery—a more manage-
able hurdle. The originators of the AADC trial acknowledge that 
the dosing parameters used in their initial clinical effort were 
suboptimal. Specifically, the researchers noted a somewhat lack-
ing transduction pattern in the putamen: whereas the prior dos-
ing parameters led to 35–40% coverage of this region as a whole, 
this corresponded with only 5–6% of AADC-expressing neurons 
within the delivery area.25 Thus, a clear priority for the reiniti-
ated trial will be to extend the putaminal coverage as well as the 
transduced cell density, which the group expects to accomplish by 
using increased vector volumes and doses.21 This solution, though 
abbreviated in their discussion, merits attention: certainly using 
magnetic resonance imaging-guided CED (convection-enhanced 
delivery) and an increased dose should increase putaminal cover-
age (even to the proposed 60% goal). Further, it is conceivable that 
the two separate concerns of transduction volume and density can 
be resolved with CED, and increased vector concentration per vol-
ume (perhaps a far greater dose). At the same time, however, efforts 
to increase volume and also increase density might represent com-
peting goals, for as volume is increased, density will decrease (all 
else being equal) and vice versa. With the steady advances in vector 
development, we argue that the vector itself should also be con-
sidered a variable that can have major consequences on transduc-
tion success. For instance, AAV1 and AAV5 are more efficacious 
than AAV2 in transduction of the primate substantia nigra (SN) 
and caudate nucleus,31,32 and several other serotypes have shown 
far superior transduction efficiency than AAV2 in rodent models, 
with respect to both volume and density.33,34 Should this improved 
efficiency translate to the Parkinsonian brain, it might allow for 
reduction in viral dose to achieve the same or greater volume 
and density of therapeutic gene expression. To the other extreme, 
assuming far higher AADC levels could be achieved through any 
or all of the above alternatives, one needs to consider the possi-
bility of increased dyskinesias, as observed in monkeys with high 
focal doses of AAV-AADC.35 While similar side effects have not 
been reported in other nonhuman primate studies or in any of the 
15 human subjects dosed a decade ago, the correlation between 
bioactivity in animal models and human studies remains uncer-
tain and a potential problem might reemerge with the proposed 
changes in CED parameters and dose. The side effects reported 
when AAV-GDNF was delivered to the SN (and beyond) using 
aggressive CED parameters in nonhuman primates18 provides 
a clear, empirical example for why one should be cautious about 
unexpected outcomes when dosing parameters are adjusted to 
significantly increase spread of vector or protein. Importantly, nei-
ther the spread of protein far outside the targeted SN, nor the side 
effects reported with aggressive CED were seen in animal studies36 
or clinical tests in PD patients37 when somewhat more moderate 
dosing parameters were employed, involving more modest CED in 
conjunction with multiple, distributed injection sites.
So what is the greater context of the original and pending fol-
low-up study? The degree by which the reiterated trial digresses 
and improves upon the original study will be vitally significant for 
the CNS GT field as a whole, where with each clinical setback the 
stakes are raised ever higher for this still-fledgling field. As with 
many emerging technologies, simultaneous advances are likely 
required, such as improved vectors, more representative animal 
models, more pointed clinical methodology that can detect nega-
tive outcomes, and a backdrop of supportive funding mechanisms.
Lenti-AADC/TH/GTP-CH1
Following publication of efficacy results in nonhuman primates 
with the trisictronic lenti-vector expressing three enzymes involved 
in dopamine production,11 an uncontrolled, open label, dose- 
escalation study was conducted in 15 PD subjects. Three ascend-
ing doses were tested, involving a 5-fold dose range.  Like the 
‘look-see’ approach applied by others, significant adjustments were 
made to the dosing parameters (e.g., needle tracts per hemisphere 
were reduced from 5 to 3; infusions per needle tract were reduced 
from several to one; infusion rate was increased from 1 µl/min 
to 3 µl /min) in the middle of the protocol. The safety profile 
looked favorable, with most adverse events being mild and deemed 
unrelated to treatment. Dose-related increases in dyskinesias 
reportedly resolved when the L-dopa dose was lowered. Modest 
improvements (from baseline) in UPDRS-motor off scores were 
seen at 6 and 12 months, roughly comparable to that seen in prior 
GT phase 1 studies. The authors concluded that they applied an 
iterative process in this trial to try to optimize delivery and that a 
more definitive double-blind placebo controlled trial will not be 
conducted until they are able to achieve an optimal dose and deliv-
ery mode, presumably requiring  further dosing iterations.
AAV/NRTN (CERE-120)
This first trophic factor approach to PD GT has seen two phase 2 
trials conducted to date,38, 39, 41 each preceded by the completion of 
an appropriate open-label phase 1 trial,37,40 as well as an extensive 
nonclinical program before that.5,36,41,42 The efficacy data for both 
phase 2 trials were mixed and disappointing, in that neither met 
the primary endpoint (UPDRS motor-off) within the prescribed 
timeframe. Notably, in the initial phase 2 trial, improvement in 
the primary clinical endpoint was seen beyond the prescribed 
assessment time (i.e., 15–18 months versus the prescribed 12 
months), offering a surprisingly positive twist to the study’s initial 
disappointment. Additionally, several other motor and quality- 
of-life endpoints achieved statistical significance at the study’s pri-
mary, 12 months time point. Moreover, of the ~50% subjects who 
remained blinded beyond the 12 months timeframe, a statistically 
significant effect was also seen on the primary endpoint, as well as 
even more secondary endpoints.37 Also, an exploratory statistical 
analysis indicated that the differences between AAV/NRTN and 
sham-surgery were highly unlikely to have occurred by chance (P 
< 0.007 and P < 0.001 at 12 and 18 months, respectively).5,41
As a perfect example of the look-see paradigm, following addi-
tional nonclinical testing,36,42 a follow-up phase 1/2b protocol was 
designed to improve efficacy by incorporating several important 
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changes, such as increasing dose and volume of the vector to the 
putamen, additional targeting of the SN directly, and extending the 
blinded assessment period by several months5; all of these changes 
were confirmed in animal models to likely improve the biological 
response to AAV2-NRTN.36,42 Still, the resulting double-blind, con-
trolled phase 2 trial also failed to show statistical significance on the 
primary endpoint.39 Thus, these results and the AAV/NRTN trial 
joined the ranks of the preceding phase 2 PD GT trials16,38 in falling 
far short of what was required to proceed into phase 3 testing.
Again, as we ask the major question of why greater efficacy was 
not achieved, we return to the issue of delivery. Here, however, the 
issue perhaps diverges from the previously entertained concern of 
putaminal coverage, to one of ineffective therapeutic gene transport 
in the pathological brain tissue. Certainly, one question posed by 
investigators is whether increasing putaminal coverage of vector 
and therefore NRTN transgene would be sufficient to improve effi-
cacy. While it is hard to argue against this rationale at face value, a 
better question is exactly how much transgene expression has been 
successfully produced previously, and how much is necessary for 
impact. Recent reexamination of autopsy specimen place estimates 
of putaminal coverage by NRTN at around 20%,37,43 which due to 
NRTN-antibody limitations, is likely underestimated.5,44 Perhaps 
more importantly, and getting to the second concern of brain trans-
port, the more recent phase 2b trial increased the NRTN dose by 
three- to fourfold and increased the volume per injection by 10-fold 
in the putamen alone. Additionally, a sizable dose was injected 
directly into the degenerating cells in the SN in an effort to assure 
adequate NRTN coverage of cells bodies to help activate repair 
pathways in these neurons. Together, these changes should have 
significantly increased NRTN expression and bioactivity events 
confirmed in animal studies36,42 (though no autopsy tissue is yet 
available from this study for confirmation); yet the clinical results 
were still not sufficiently robust. Conversely, in primate MPTP and 
advanced-age primate models of PD, significant neuronal protec-
tion and restoration was achieved with putaminal coverage well 
below 10% coverage.45,46 Thus, whether the extent of putaminal 
coverage by vector is the major factor in achieving robust clinical 
improvement is unclear, for neither that nor the addition of target-
ing the SN was sufficient to enhance the clinical readout. These data 
warn that merely improving blanket gene delivery coverage may 
not hold the key to achieving a desired outcome.
If vector transduction alone is not a major concern, what else 
might account for the lack of efficacy? One possibility has to do with 
the degenerative state of PD, and how this may affect therapeutic 
protein transport through brain circuits. With regard to AAV/
NRTN, one possibility is the serious deficiency of axonal transport 
in PD patients. Such deficiencies have been posited as a major rea-
son why, despite areas of intense NRTN expression in the targeted 
putamen, little NRTN was seen at the distal SN, where the protein 
product was intended to be transported to achieve a robust neu-
rotrophic response.37,39,43,44 The topographic relationships between 
SN neurons and their putaminal projection fibers predicates that 
even a small area of protein expression in the putamen should 
produce a proportional area of detectable protein in the SN—a 
finding confirmed in several nonhuman primate studies with AAV-
NRTN.44 However, as very little NRTN was seen in the SN of the 
PD autopsy tissue, it appeared that neuronal pathology in the aged 
human PD brain was more severe than that of animal models, pre-
venting NRTN transport from the putamen to the SN. Aside from 
axonal transport (and related axonopathy) concerns, other patholo-
gies may also diminish the anticipated effect of neurotrophic fac-
tor support, even in consideration of direct targeting to the SN cell 
bodies. For instance, α-synuclein (a protein whose accumulation 
in dopamine neurons serves as a major pathogenic event in PD) 
can mediate downregulation of the transcription factor Nurr1 and 
its downstream target, the GDNF/NRTN RET receptor,47–49 directly 
mitigating GDNF/NRTN signaling, and thus impeding the thera-
peutic outcome from occurring. These summations strongly argue 
for animal models that better reflect multiple elements of the clinical 
condition (e.g., varying degrees of axonopathy, including persistent 
axonal dysfunction in currently surviving neurons) and/or recruit-
ing less severely advanced patients, which may retain better trans-
port and less-pathological antineurotrophic molecular cascades.
AAV/GDNF
The questions raised by the AAV/NRTN program and clinical 
trials are directly pertinent to this nascent clinical program, for 
despite differential developmental expression profiles,50 supra-
physiological levels of GDNF and NRTN produce virtually indis-
tinguishable in vivo efficacy profiles.51,52 Therefore, given the same 
testing conditions and dosing parameters, expectations that sub-
stituting one protein for the other alone will produce a sufficiently 
different clinical outcome are most likely to disappoint. The inves-
tigators pursuing the AAV/GDNF clinical trial could perhaps be 
adopting a look-see approach by improving upon key aspects of 
past studies (namely AAV/NRTN). As such, one strategy includes 
expansion upon putaminal coverage volume via more aggressive 
CED. This strategy follows the “improved delivery” logic, and is 
thus prone to the same pitfalls as many past efforts in PD GT. 
Simply increasing putaminal coverage of GDNF as a sole means 
to enhance efficacy in the clinic ignores the concerns of compro-
mised axonal transport, for instance. It also overlooks concerns 
of α-synuclein accumulation on dampening GDNF signaling.47–49 
Either or both of these factors may account for the higher respon-
sivity in earlier versus later-stage subjects in the second AAV/
NRTN phase 2 study39 and are not apparently being accounted 
for in the nascent AAV2/GDNF protocol. Thus, the AAV/GDNF 
study in many ways mirrors the past AAV/NRTN studies (but 
without clear attempts to circumvent transport deficiencies by 
directly targeting the SN). Thus, without significant further inno-
vation, we worry that this latest clinical endeavor may be relying 
too heavily on incremental delivery enhancement as the primary 
means to achieve a substantially superior clinical outcome.
HOW FAR HAVE WE COME?
Now a full decade after the first clinical testing of PD GT began, 
the disappointments can overshadow the successes. Yet, the col-
lective successes are both important and concrete, and are pre-
cisely what the next decade of PD GT research will move forward 
from: safety, controllability, and quality manufacturing.
Safety of CNS GT
Just a decade ago, when the first PD GT clinical trial was being 
launched, safety of CNS GT was the major concern to many 
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investigators and nearly all regulatory agencies, investors, and 
potential Pharma industry partners. However, over the past 10 
years, these issues have largely evaporated, in no small part due to 
the contributions of the programs reviewed in this paper. Despite 
numerous concerns on nearly everyone’s minds, none of the tri-
als noted any troubling safety problems; the most consistent AEs 
(adverse events) reported for all the studies were related to the 
stereotactic surgical procedure and those were similar to what has 
been accepted as tolerable for deep brain stimulation, a stereotac-
tic surgical procedure for PD long-since approved by European 
regulatory agencies and the FDA. Conversely, all three phase 2 PD 
studies observed a substantial placebo response (i.e., improvement 
from baseline in the sham control group), thus indirectly verifying 
the safety of stereotactic administration of GT products into the 
brain.16,38,39,53
The CNS GT approach itself can also be deemed as safe—data 
from the PD GT trials to date show a remarkably clean safety pro-
file, with none of the problems seen when non-GT methods have 
been used in an attempt to provide chronic, exogenous bioactive 
protein (e.g., protein aggregation, loss of bioactivity, induction of 
neutralizing antibodies, etc.) In fact, the safety record for PD GT 
collectively appears more favorable than several prior approaches 
intended to deliver chronic protein for human neurodegenera-
tive diseases (e.g., NGF for Alzheimer’s; GDNF and fetal tissue 
transplantation for PD), in that far fewer serious adverse events 
have been noted in the GT studies compared to the competing 
delivery approaches.54–59 Another concern in the field a decade ago 
involved the potential impact of preexisting neutralizing antibod-
ies (nAbs) to viral vectors (e.g., AAV, for which humans can have 
measurable titers). However, with regard to the brain, nAbs so 
far appear to be inconsequential towards any local inflammatory 
reaction, transgene expression, or long-term bioactivity.5 Lastly, 
the need to regulate protein expression in a safe and effective 
manner, or even shut down expression completely if serious safety 
issues arise, was a safety issue raised by select researchers. To date, 
there have been no adverse effects of chronic expression, and 
regulatory control appears to be more an incremental enhance-
ment than an absolute necessity. However, as doses and transduc-
tion overall are increased through improved targeting (e.g., the 
reinitiated AAV/AADC trial) and/or vector design, the need for 
a regulatable vector may reemerge as an important consideration. 
Thus, GT in the context of PD has proven it to be among the safest 
approaches developed for long-term, targeted delivery of proteins 
to the brain—a benchmark that has shifted safety assumptions for 
the GT field as a whole.
Controlled and predictable bioactive protein 
expression
The PD clinical trials have also generated convincing evidence that 
GT can meet its most important objective: providing the means to 
achieve chronically controlled and predictable bioactive protein 
expression, targeted to specific brain sites in animals and human 
patients. In animal studies, clear dose–response relationships have 
been established in both rats and monkeys52,60,61 demonstrating 
the ability to control amount of protein production and volume of 
expression by manipulating vector genome dose. Moreover, long-
term, targeted expression of biologically active protein has been 
achieved following a single administration of the vector in rats 
for at least 4–5 months for GAD,9 and 20 months for NRTN.62 
In nonhuman primates, this has been established for at least 56 
weeks for GAD,10 1-year for NRTN,61 6–8 years for AADC.25,35 
While human expression data are more limited, long-term, bioac-
tive protein expression has nonetheless been confirmed for over 4 
years for both AAV-AADC, using a PET imaging surrogate21 and 
more directly for AAV-NRTN, demonstrating long-term biologi-
cally active protein expression via immunohistochemistry in tis-
sue from postmortem brains of previously treated subjects.39
Manufacturing
Advances in process development and manufacturing have made 
it possible to produce sufficient current good manufacturing prac-
tice) quantities of vector in a cost-effective manner to supply mul-
ticenter clinical trials as well as product commercialization; thus, 
cost-of-goods is no longer the impediment to commercialization 
that it was viewed to be by many just a decade ago. As described 
in better detail elsewhere,63 one of the great successes in the past 
decade has been the scalability of vector production, from the 
original plated HEK293 cell production without the addition of 
helper virus,64 to the current suspension culture methods,63 bacu-
lovirus expression vector systems (e.g.,),65 HSV-based produc-
tion systems66 and others, with possible titer generation upwards 
of 1 × 1014 viral genomes per liter of cells. Coupled with the high 
purity of ion-exchange chromatography, and current good manu-
facturing practice realization through vector core facilities, vector 
production can be fast, reliable, highly pure, and affordable.
WHERE DO WE GO NEXT?
In sum, the progress achieved over the past decade with the PD 
GT programs and their clinical trials has created the irony that GT 
has worked as it was designed but not as intended. That is, despite 
successfully providing safely targeted and controlled bioactive 
protein for very long periods of time in both animal and human 
brain, the efficacy data generated in the PD clinical trials did not 
demonstrate sufficiently robust or consistent benefits to patients, 
compared to that achieved by placebo controls.
Is PD the disease to bank our CNS GT expectations 
on?
A fundamental question that has emerged following completion 
of the nine PD trials is whether this disease presents too great 
a challenge to continue to promote as a prototype platform for 
launching GT as a transformative approach for broadly treating 
CNS diseases. PD is recognized to be an extremely complex dis-
ease involving many different genetic and environmental etio-
logic and pathologic variables (Table 1), as well as degeneration 
of many nondopaminergic and nonmotor systems,3,67 for which 
the cause-effect relationships are incompletely understood, mak-
ing the success of any novel interventional approach less certain. 
Even if we focus narrowly on the continued need for better treat-
ment for the motor impairments, significant practical challenges 
complicate that endeavor. Some of the most grievous challenges 
include the heavy reliance on highly subjective and variable clini-
cal assessment tools, the lack of validated biomarkers or clearly 
effective/predictive surrogate measures (attempts to use PET 
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imaging notwithstanding), high variability in degree and scope 
of individual-patient symptoms from day to day and even hour 
to hour, the large but variable placebo response often seen in PD 
trials, and concerns regarding the predictive validity of currently 
used animal models. To this last point, the fact that most of the 
GT PD program produced clear evidence for robust, positive data 
in the most widely accepted animal models used for PD and yet 
failed to replicate the magnitude or consistency of these effects in 
PD patients, necessarily raises a question of whether the predic-
tive validity of these models is sufficient for establishing nonclini-
cal proof of concept (see Table 1).
These difficulties in mind, would the CNS GT community find 
greater opportunity for growth and success in focusing on alter-
native diseases? Finding a model disease with which to launch a 
sea change in CNS GT has been notoriously challenging. Some of 
the ongoing CNS GT efforts include lysosomal storage diseases, 
leukodystrophies, amyotrophic lateral sclerosis, Alzheimer’s, epi-
lepsies, and cancers. A cursory evaluation of these diseases and 
their treatment hints at both unique and familiar challenges. A 
key divergent challenge has been vector targeting issues: some 
CNS diseases, including lysosomal storage diseases and leu-
kodystrophies warrant nonneuronal cell transduction and/or 
global CNS delivery, neither of which has been adequately real-
ized with current technology. Some of the convergent challenges 
include matching the predictive ability of animal models to clini-
cal success. With amyotrophic lateral sclerosis, for instance, the 
commonly used SOD1 mouse line has benefited from preclini-
cal successes (e.g.,),68 which translated poorly in humans, where 
patients in the treatment group actually deteriorated more rap-
idly.69 Disease complexity is not unfamiliar to the Alzheimer’s or 
epilepsy fields, which may benefit most directly from the specific 
growing pains and lessons of PD GT.
Improving our odds of success
Are we overlooking accessible means of reaching heightened clini-
cal success with PD GT? Two of the major concerns highlighted 
in the PD GT trials included weak transduction and likely protein 
product transport issues in the pathological brain tissue. As dis-
cussed earlier, in addition to improved delivery technologies such 
as CED, there are foreseeable advantages of alternating the vec-
tor serotype or using engineered vectors to improve transduction 
directly, rather than resorting simply to higher vector dosing and 
infusion volumes. The perceived challenge here is in the resources 
required to obtain regulatory approval for using unique viral enti-
ties, whereas this hurdle has long been cleared for AAV2. Recent 
discussions to streamline the regulatory process for newly devel-
oped vectors are formalizing and hopefully may clear a path for 
improved vector usage in the clinic.70 Regarding the challenges of 
the pathology itself, if the degenerative state were a major obsta-
cle for therapy, would earlier treatment not be more efficient and 
potentially successful? A recent exploratory analysis of the AAV2-
NRTN phase 2b data suggests so: in the study earlier-stage PD sub-
jects (defined here as those 5 or fewer years postdiagnosis) showed 
much greater clinical benefit from AAV-NRTN than did those 
treated at 10 or more years postdiagnosis.39 This elevates the age-
old issue in the neurodegeneration field, particularly with regard to 
neurotrophic factor intervention, regarding whether earlier-stage 
patients might indeed respond far better and more reliably than 
those currently enrolled in experimental treatments. Thus, two 
questions emerge that will command significant research and 
regulatory attention going forward: how quickly dying neurons 
reach an irreversibly degenerated state,71 and how early in the dis-
ease process experimental treatments will be warranted in patient 
volunteers.39 Progress in clinical biomarker research (such as that 
recently described)72 will undoubtedly shape the earlier interven-
tion efforts and may even help establish surrogate endpoints to 
permit a more biometrically equilibrated scoring system (Table 3).
Seeking alternative animal models
In light of the consistent disconnect between preclinical and clini-
cal successes in PD GT, a step back from the clinic might reenvi-
sion the problem of delivery to one of predictive power of animal 
models. The overreliance on acute toxin-based PD models (e.g., 
the everpopular 6-OHDA and MPTP models) limits our explora-
tion of treatment options and models that encompass more of the 
pathogenic variables (Table 1) with less focus on limited patho-
logic or behavioral changes may yield both conventional and 
biomolecular alternatives. One paradigm gaining momentum is 
that focusing on the pathological sequelae of α-synuclein overex-
pression (aggregation of which is a key pathogenic event in PD), 
which can result in the death of the mid-brain dopamine neurons 
affected in PD.47,48,73–76 Perhaps most valuable with regard to GT 
shortcomings to date is the observation that overexpression of 
α-synuclein in rats leads to axonal transport deficits and gradual 
dysfunction of dopamine processes prior to frank cell death, a 
process akin to that described in PD.73 Moreover, these increased 
levels of α-synuclein can inhibit the ability of GDNF to protect 
degenerating dopamine neurons, ostensibly through downregu-
lation of the transcription factor Nurr1 and its downstream tar-
get, RET—the GDNF receptor.47,48,75 By inference, such findings 
provide a putative basis respectively for challenges of retrograde 
GT transport and neurotrophic factor bioactivity. This model 
involving overexpression of α-synuclein is still far from fully 
characterized and is certain to be an incomplete representation 
of the disease. It is already clear that the protein overexpression 
required to induce the PD-like pathology far surpasses human 
pathological levels, while the focus on a singular molecular moi-
ety recapitulates a strategy that has ensnared the Alzheimer’s field 
for years (i.e., β-amyloid transgenics). Nonetheless, progress at the 
preclinical level, even discoveries well within reach, may provide 
robust opportunities for substantially increasing the momentum 
for research and development in GT.
Reaching across the aisle
From regulatory hurdles, to endpoints and even overarching trial 
design, the conventional pharmaceutical approach to treating 
PD might seem fully distinct from GT efforts, but yet a solution 
may come from aligning our strengths—achieving a sum greater 
than the parts. Where the conventional and GT-based approaches 
have already been linked to some extent through the prodrug 
strategy (i.e., AADC—enhancing the therapeutic benefit of oral 
levodopa treatment) this complementation could seemingly 
extend beyond the prodrug scenario; as examples, α-synuclein 
aggregation inhibitors could improve retrograde vector transport, 
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supporting superior nigrostriatal transduction, or Nurr1 agonists 
could potentiate the effects of neurotrophic factors like NRTN and 
GDNF. A further envisioning of GT for use in conjunction other 
nonconventional therapies, such as deep brain stimulation, seems 
reasonable at a regulatory level (perhaps requiring little additional 
surgical intervention to achieve both vector delivery and electrode 
implantation), and might be an outside strategy for achieving the 
next critical victory in PD GT.
What can we learn from the history of novel 
therapeutics?
The history surrounding the development of monoclonal antibod-
ies (mAb) into the powerful biopharmaceuticals they have now 
become provides a comparative perspective regarding the current 
status of PD GT. With the early fervor over mAbs in the 1980s to 
early 90s, one company (Janssen Biotech, Horsham, Pennsylvania) 
spent years of intense effort and hundreds of millions of dollars77 
developing its lead mAb product, nebacumab or Centoxin, to 
treat sepsis. However, following promising data in animal models 
and even some approvals in Europe for other indications, a pivotal 
trial failed miserably.78 Centocor’s first mAb approval (infliximab; 
Remicade), initially for Crohn’s disease and later for rheumatoid 
arthritis, was not achieved until 6 years after the Centoxin/sep-
sis failure, but now enjoys extremely high success both clinically 
and financially,79 and is just one of nearly 30 different mAb drugs 
contributing to one of the fastest growing therapeutic areas in bio-
tech.80 This example, and many others involving similarly novel, 
transformational biomedical technologies (e.g., antisense technol-
ogy,81 informs us that the types of disappointments seen with GT 
for PD can absolutely precede major successes, but that such an 
about-face requires a renewed approach, avoiding the same mis-
calculations made previously.
Bearing in mind the clear differences between CNS and periph-
eral targets for GT, the successes in a sister program—namely 
hemophilia B—should still serve as a valuable model for PD GT 
researchers. Here, the look-see effect that has proven something of 
an impediment to PD innovation has been the mainstay compo-
nent that has allowed for gradual, real progress. To distill a tremen-
dous amount of work for the purposes of example, hemophilia GT 
saw major preclinical successes, such as AAV-mediated recovery of 
clotting function in Factor IX (FIX)-deficient dogs,82,83 lead to an 
unanticipated lack of secreted protein product in humans,84 fol-
lowed by a shift in preclinical vector targeting from muscle to liver, 
which, when returned to the clinic led to a short-lived therapeutic 
benefit,85 again not anticipated from the animal models. With the 
advent of a higher efficacy vector (i.e., self-complementary AAV),86 
codon-optimized genes,87 and testing of more efficacious vectors 
(i.e., AAV8 for improved liver transduction),87 a recent clinical trial 
benefited by long-term (albeit low) gene delivery.88 Now using a fur-
ther optimized point mutant of FIX with sevenfold higher activity, a 
clinical trial is ongoing.89 Of course, the monogenic nature of hemo-
philia B, versus the far more complex etiology of PD, has narrowed 
the prior field’s efforts toward improving delivery and persistence, 
largely avoiding the key challenge of transgene appropriateness. 
Still, even in the hemophilia GT arena, there clearly continues to be 
a need for iteration and continuity between bench and clinic, and 
this serves as proof that the look-see approach can work with perse-
verance, further innovation and continuing resources.
PARTING THOUGHTS
Without proper reflection, the generally disappointing efficacy 
data generated in the PD GT clinical trials might easily over-
shadow the significant progress that has been achieved in these 
same studies. Over the course of translating animal studies into 
Table 3 Resolving key obstacles to facilitate new Parkinson’s disease therapies
Obstacle/challenge Impact on clinical tests Possible path toward a solution
Significant variability in patient’s 
symptoms
Greatly increases “noise”, 
reducing probability of 
detecting genuine benefit
Near-term focus: Develop objective, clinically-meaningful, validated, “at-home” 
measuring tools for routine, repetitive testing to complement existing clinical tools
   Magnitude and scope vary from hour-to-
hour and day-to-day, rendering scheduled 
clinical assessments mere “semirandom” 
snapshots of patient’s status
Standard clinical assessment tools are 
suboptimal; e.g., highly subjective; 
variable from rater-to-rater; prone to 
significant rater (clinical) bias
Introduces variability, 
reducing probability of 
detecting benefit
Near-term focus: Rely more on improved at-home assessments to complement clinical 
tools (above)
Longer-term focus: Develop more objective clinical assessment tools
Lack of reliable, objective, validated 
biomarkers, and surrogate endpoints
Exclusive dependence 
on subjective clinical 
endpoints (above)
Near- and longer-term focus: Continue concerted research effort (e.g., MJFF 
“Parkinson’s progressive markers initiative”) to identify objective biomarkers that can 
be used to define subpopulations of patients; Also, utilize these biomarkers to identify 
earlier-stage patients, and as surrogate end-points
Animal models lack predictive value Reduces ability to refine 
or objectively select 
treatments to test in 
humans
Near and longer-term focus: Develop models that (1) incorporate more of the 
pathogenic events of Parkinson’s disease; (2) attempt to match magnitude of 
these pathogenic events to Parkinson’s disease and provide temporal windows for 
intervention throughout the pathology; (3) move away from univariate models in favor 
of multi-variate models; (4) incorporate aging as a major covariate; and (5) manifest 
persistent (steady-state), intraneuronal dysfunctions   With exception of dopamine synaptic 
modulators, they have universally been 
ineffective in predicting outcomes in 
Parkinson’s disease clinic
Increases risk that 
treatment will fail in 
clinical trial
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clinic trials, these programs helped transform the entire field of 
GT. They established that GT could be accurately targeted to the 
brain in a safe and effective manner, that the viral vector is able to 
induce neurons to produce controlled and predictable protein for 
years, and that biological responses can be induced in degenerating 
neuronal systems in human brains. While it is true that the clini-
cal efficacy achieved to date is not nearly as robust or reliable as 
required, it is also true that each of the three completed controlled 
studies has nonetheless produced some evidence for a clinical 
benefit exceeding that achieved by sham procedure. The fact that 
the GT approaches to PD worked as designed but did not achieve 
the magnitude of clinical benefit intended casts caution towards 
the hurried repetition of modestly-altered procedures, and may 
warrant a retargeting of the PD GT trajectory, starting back at the 
laboratory bench. Solid victories, akin to those won over safety 
and longevity concerns, are the key to continued momentum. 
Given the therapeutic power that biopharmaceuticals are begin-
ning to show and the value that GT has yielded with regards to its 
ability to provide safe and effective delivery of proteins, with cau-
tious continuity it is not hard to imagine that GT will be an impor-
tant contributor and benefactor of more effective treatments for 
PD and other CNS diseases. In the meantime, questions will and 
should be raised about the best ways to move forward. For PD 
specifically, a near-term focus on developing more effective tools 
for measuring motor performance in people with PD would likely 
provide many tangible benefits for trial design and execution, as 
would the development of biomarkers and surrogate endpoints. 
Moreover, the development of more sophisticated animal mod-
els that focus on key pathogenic events rather than symptoms or 
univariate end-stage pathologies will likely yield improvements in 
these models’ predictive value for GT intervention.
The glass is half full. Attending to these important consider-
ations and implementing the lessons of our past we can reach the 
success we all envision, and advance the field ever forward.
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